These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25038076)

  • 1. Not so "good" cholesterol.
    Kritharides L
    BMJ; 2014 Jul; 349():g4664. PubMed ID: 25038076
    [No Abstract]   [Full Text] [Related]  

  • 2. With statin co-administration, drugs designed to increase HDL have no impact on cardiovascular outcomes.
    Durrington PN
    Evid Based Med; 2015 Feb; 20(1):12. PubMed ID: 25249694
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients.
    Keene D; Price C; Shun-Shin MJ; Francis DP
    BMJ; 2014 Jul; 349():g4379. PubMed ID: 25038074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CardioPulse: is raising HDL a valid treatment target? : epidemiological studies show a relationship between high HDL and lower cardiovascular events but subsequent research casts doubt on treatment benefit.
    Taylor J
    Eur Heart J; 2013 Apr; 34(16):1174. PubMed ID: 23604754
    [No Abstract]   [Full Text] [Related]  

  • 5. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
    Bajnok L
    Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ebbs and flows in the development of cholesterol-lowering drugs: prospects for the future.
    Hajhosseiny R; Sabir I; Khavandi K; Wierzbicki AS
    Clin Pharmacol Ther; 2014 Jul; 96(1):64-73. PubMed ID: 24699033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
    Ballantyne CM; Shah S; Kher U; Hunter JA; Gill GG; Cressman MD; Ashraf TB; Johnson-Levonas AO; Mitchel YB
    Am J Cardiol; 2017 Feb; 119(3):388-396. PubMed ID: 27956003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional assessment of HDL: Moving beyond static measures for risk assessment.
    Rosenson RS
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):71-5. PubMed ID: 20094763
    [No Abstract]   [Full Text] [Related]  

  • 10. HDL- cholesterol: a nut too hard to crack?
    Kaski JC
    Cardiovasc Drugs Ther; 2012 Oct; 26(5):433-4. PubMed ID: 22825352
    [No Abstract]   [Full Text] [Related]  

  • 11. Are human CETP mutations and CETP-inhibiting drugs a good or a bad deal?
    Luft FC
    J Mol Med (Berl); 2006 Aug; 84(8):625-7. PubMed ID: 16855847
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment options for low high-density lipoproteins.
    Hafiane A; Kellett S; Genest J
    Curr Opin Endocrinol Diabetes Obes; 2014 Apr; 21(2):134-9. PubMed ID: 24535232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-density lipoprotein subfractions--what the clinicians need to know.
    Pirillo A; Norata GD; Catapano AL
    Cardiology; 2013; 124(2):116-25. PubMed ID: 23428644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of enduracin on the level of cholesterol in flying personnel].
    Preobrazhenskiĭ VN; Matveev AA
    Aviakosm Ekolog Med; 1997; 31(3):43-4. PubMed ID: 9244507
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of HDL-modifiers on cardiovascular outcomes: a meta-analysis of randomized trials.
    Verdoia M; Schaffer A; Suryapranata H; De Luca G
    Nutr Metab Cardiovasc Dis; 2015 Jan; 25(1):9-23. PubMed ID: 25439661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?
    Otocka-Kmiecik A; Mikhailidis DP; Nicholls SJ; Davidson M; Rysz J; Banach M
    Prog Lipid Res; 2012 Oct; 51(4):314-24. PubMed ID: 22609245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on therapies targeting HDL: the mystery continues.
    Virani SS; Ballantyne CM
    Curr Opin Lipidol; 2011 Dec; 22(6):514-6. PubMed ID: 22101565
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical benefit from pharmacological elevation of high-density lipoprotein cholesterol: meta-regression analysis.
    Hourcade-Potelleret F; Laporte S; Lehnert V; Delmar P; Benghozi R; Torriani U; Koch R; Mismetti P
    Heart; 2015 Jun; 101(11):847-53. PubMed ID: 25872524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The continuing complexities of high-density lipoprotein metabolism in drug discovery and development.
    Suckling K
    Expert Opin Ther Targets; 2007 Sep; 11(9):1133-6. PubMed ID: 17845140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug designed to raise HDL levels falls down.
    Honey K
    J Clin Invest; 2007 Feb; 117(2):282. PubMed ID: 17273546
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.